Siatis Perry C 4
4 · AbbVie Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
AbbVie (ABBV) EVP/GC Perry C. Siatis Sells Shares
What Happened
Perry C. Siatis, Executive Vice President, General Counsel and Secretary of AbbVie, disposed of a total of 33,518 AbbVie shares in connection with an option-related tax/withholding transaction and subsequent open-market sales. On 2026-02-27 Siatis surrendered 14,850 shares to cover exercise price or tax liability (reported as code F) at a weighted average of $232.08 for ~$3.45M. On 2026-03-02 Siatis sold 18,668 shares across multiple open-market transactions at weighted average prices of $233.51, $234.66 and $235.26, generating proceeds of about $4.38M. Combined proceeds/consideration across these dispositions are roughly $7.82M. These are sales/withholdings (not purchases) and thus do not represent a new purchase signal.
Key Details
- Transaction dates: 2026-02-27 (tax/withholding surrender) and 2026-03-02 (open-market sales). Filing date: 2026-03-03 (appears timely under the two-business-day rule).
- Share counts and reported values:
- 14,850 shares surrendered (code F) @ $232.08 (weighted avg) = $3,446,388
- 5,777 shares sold @ $233.51 (weighted avg) = $1,348,987
- 10,291 shares sold @ $234.66 (weighted avg) = $2,414,886
- 2,600 shares sold @ $235.26 (weighted avg) = $611,676
- Total disposed: 33,518 shares for ~$7,821,937
- Shares owned after transaction: not specified in the excerpt of the filing.
- Notable footnotes:
- F1–F3 indicate the reported prices are weighted averages from multiple sale prices within the listed ranges (233.00–233.99; 234.14–235.12; 235.14–235.36). The filer will provide specifics on request.
- Code F denotes shares surrendered to cover exercise price or tax liability (i.e., withholding), not a cash purchase.
- Timeliness: Filing date (2026-03-03) follows the transactions on 02-27 and 03-02 and appears to meet the standard Form 4 filing window (filed within two business days).
Context
- The sequence (shares surrendered for tax/withholding, then additional open-market sales) is consistent with exercising equity awards followed by withholding and sales to cover taxes or take proceeds. The filing shows dispositions, which are routine for option exercises and tax-withholding; they are not the same signal as an insider purchase.
- No 10% owner or gift/award indicators are present in this excerpt.
Insider Transaction Report
- Tax Payment
Common Stock, $0.01 par value
2026-02-27$232.08/sh−14,850$3,446,388→ 23,287 total - Sale
Common Stock, $0.01 par value
[F1]2026-03-02$233.51/sh−5,777$1,348,987→ 17,510 total - Sale
Common Stock, $0.01 par value
[F2]2026-03-02$234.66/sh−10,291$2,414,886→ 7,219 total - Sale
Common Stock, $0.01 par value
[F3]2026-03-02$235.26/sh−2,600$611,676→ 4,619 total
Footnotes (3)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.